Infections in neuro-oncology
Authors:
- 15 October 2011
- journal article
- Published by Springer Nature in Neurological Sciences
- Vol. 32 (2) , 233-236
Abstract
Infections represent a serious and frequent complication in neuro-oncology patients. Decreased immune defences, along with poor nutritional status are the main predisposition factors. The combined therapeutic strategies of chemotherapy and radiotherapy may favour bone marrow depression and further increase the risk of developing opportunistic infections in brain tumour patients. The spectrum of infections in neuro-oncology patients is large and includes opportunistic infections by bacteria, viruses, fungi and parasites. Importantly, a high index of suspicion for opportunistic infections in general should be maintained, especially in glioma patients receiving dose-dense schedules of temozolomide. After neurosurgical procedures, infections most commonly present as meningitis, subdural empyema, or cerebral abscess. Infections represent a frequent and possibly serious complication in general immunocompromised oncology population. It should be underlined that infections are not limited to immunocompromised patients, being also present at the early disease stages, especially due to therapeutic strategies (chemo and radiotherapy, surgical procedures). Therefore this issue deserves more attention in neuroncology setting.Keywords
This publication has 19 references indexed in Scilit:
- Immunosuppression in Patients with High-Grade Gliomas Treated with Radiation and TemozolomideClinical Cancer Research, 2011
- Supportive care in neurooncologyCurrent Opinion in Oncology, 2010
- The safety of temozolomide in the treatment of malignanciesExpert Opinion on Drug Safety, 2009
- Operative intracranial infection following craniotomyNeurosurgical Focus, 2008
- How Lymphotoxic Is Dose-Intensified Temozolomide? The Glioblastoma ExperienceJournal of Clinical Oncology, 2005
- Selective CD4+ Lymphopenia in Melanoma Patients Treated With Temozolomide: A Toxicity With Therapeutic ImplicationsJournal of Clinical Oncology, 2004
- Risk Factors for Postcraniotomy Surgical Site Infection after 1,3‐Bis (2‐Chloroethyl)‐1‐Nitrosourea (Gliadel) Wafer PlacementClinical Infectious Diseases, 2003
- Blood–brain barrier breakdown in septic encephalopathy and brain tumours*Journal of Anatomy, 2002
- Promising Survival for Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Concomitant Radiation Plus Temozolomide Followed by Adjuvant TemozolomideJournal of Clinical Oncology, 2002
- Morbidity and Survival after 1,3-6/s(2-chloroethyl)-1-Nitrosourea Wafer Implantation for Recurrent Glioblastoma: A Retrospective Case-matched Cohort SeriesNeurosurgery, 1999